Vir Biotechnology Q3 2026 Earnings: Lower R&D Spending Narrows Net Loss

Vir Biotechnology (Nasdaq: VIR) reported Q3 2026 revenue of negative $188,000 for the quarter ended September 30, compared with $240,000 a year earlier, while GAAP basic and diluted net loss per share narrowed to $0.57 from $1.17. The smaller loss was driven mainly by lower R&D expense, reflecting a prior-year $75 million milestone and current-period collaboration cost recoveries, while quarter-end cash, cash equivalents and investments stood at $901.3 million.

Core Financial Results

Revenue remained minimal relative to Vir Biotechnology’s expense base, with negative $200,000 of license and collaboration revenue partly offset by $12,000 of grant revenue. The improvement in earnings therefore came from lower operating expenses rather than revenue growth.

R&D expense fell approximately 47% to $80.0 million. The main drivers were the absence of the $75.0 million VIR-5525 first-in-human milestone recorded in Q3 2025 and cost recoveries associated with the Astellas and Norgine collaborations. Higher manufacturing costs for the oncology and chronic hepatitis delta programs provided a partial offset. SG&A expense rose about 10% because of higher advisory and legal fees.

Weighted-average shares increased to 169.3 million from 138.9 million. As a result, the reduction in per-share loss was larger than the percentage reduction in total net loss.

Pipeline and Collaboration Progress

Chronic Hepatitis Delta

The pivotal ECLIPSE program is the most immediate clinical focus. Topline results from ECLIPSE 1, which compares monthly elebsiran and tobevibart with deferred treatment, remain expected in Q4 2026. Results from ECLIPSE 2 and ECLIPSE 3 are expected in Q1 2027.

Vir plans to use data from all three studies as part of a comprehensive global filing package. The company also scheduled expanded Phase 2 SOLSTICE results for presentation on November 8, 2026.

Oncology

VIR-5500 received FDA Fast Track designation for late-line metastatic castration-resistant prostate cancer and achieved what the company described as proof of concept. The candidate is currently in a Phase 1 trial covering six dose-expansion cohorts, with multiple pivotal trials planned for 2027 in partnership with Astellas.

For VIR-5818, Vir plans to add backfill cohorts with a more homogeneous patient population following FDA feedback, with the goal of refining dose and schedule selection. Dose escalation in combination with pembrolizumab remains underway. VIR-5525 also continues enrollment as both a monotherapy and in combination with pembrolizumab.

Vir separately entered a collaboration and license agreement with Gilead covering three PRO-XTEN dual-masked T-cell engager candidates. The agreement provided $90 million in cash consideration, consisting of a $65 million upfront payment and a $25 million equity investment at a 30% premium. Vir could also receive up to $45 million in near-term preclinical milestones and as much as $1.74 billion in additional development, regulatory and commercial milestones, plus tiered royalties. These future payments are contingent on specified milestones being achieved.

Profitability, Liquidity, and Capital Structure

Total other income of $8.3 million, including $9.3 million of interest income, reduced the gap between the $104.7 million operating loss and the $96.3 million net loss. Interest income was nearly unchanged from the prior-year quarter.

Cash, cash equivalents and investments totaled $901.3 million at September 30, 2026, down $106.5 million during the quarter. That balance excluded the $90 million cash consideration associated with the Gilead collaboration. Higher manufacturing costs for the clinical pipeline remain an expense to monitor as Vir approaches pivotal hepatitis delta results and prepares for planned oncology trials.

Financial Guidance

Vir maintained its liquidity outlook, continuing to expect existing cash, cash equivalents and investments to fund operations into the second half of 2028. The runway is based on the company’s current operating plans and therefore remains sensitive to clinical timelines, manufacturing requirements and changes in development spending.

Recent Insider Transactions

The supplied six-month insider summary shows 76,731 shares purchased across eight transactions and 25,579 shares sold across three transactions, resulting in net purchases of 51,152 shares. Insiders held 11.14 million shares, and net purchases represented 0.50% of the reported insider position.

Among the latest 10 reported records, eight were zero-price stock awards and two were direct sales. The awards did not include quantities in the supplied data, so the records should not be interpreted as open-market purchases.

The two reported sales had a combined value of $33,822. Individual insider transactions alone do not establish management’s view of the company’s prospects.

Risks Investors Need to Watch

• Dependence on pivotal hepatitis delta data: ECLIPSE 1 results are expected in Q4 2026, followed by ECLIPSE 2 and ECLIPSE 3 in Q1 2027. Safety, efficacy or timing issues could affect the planned global filing package.
• Early-stage oncology execution: VIR-5500 has achieved proof of concept and Fast Track designation, but it remains in Phase 1, while pivotal trials are not expected to begin until 2027. VIR-5818 and VIR-5525 are also still in early clinical development.
• Ongoing spending without meaningful revenue: Quarterly revenue was negative and did not offset the company’s $104.5 million operating expense base. Liquidity declined by $106.5 million during the quarter despite the narrower loss.
• Cash-runway assumptions: Guidance into the second half of 2028 depends on current operating plans. Higher manufacturing costs, additional trials or development delays could alter the spending trajectory.
• Contingent collaboration economics: Most potential payments from Gilead depend on future preclinical, clinical, regulatory and commercial milestones and are not guaranteed.

Summary

Vir Biotechnology’s Q3 2026 net loss narrowed mainly because the prior-year period included a large one-time milestone and the latest quarter benefited from collaboration cost recoveries, not because of revenue growth. The company retains $901.3 million in cash and investments and reaffirmed its runway into the second half of 2028. The next major operating tests are the ECLIPSE readouts, execution of planned VIR-5500 pivotal trials and management of development costs as the pipeline advances.